Bone Biologics Corp

For the period ended Dec 31, 2023. Filed Feb 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 21, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Deficit

Consolidated Statement of Stockholders’ Equity

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2021	43,189	43	77,051,020	(70,475,607)	6,575,456
Fair value of vested stock options issued to employees and directors	-	-	266,633	-	266,633
Proceeds from sale of common stock units in public offering, net of offering costs $686,822	15,741	16	4,429,844	-	4,429,860
Fair value of warrant liability recognized upon issuance of warrants	-	-	(4,429,860)	-	(4,429,860)
Exercise of warrants	4,890	5	(5)	-	-
Extinguishment of warrant liability upon exercise of warrants	-	-	589,839	-	589,839
Net Loss	-	-	-	(1,484,620)	(1,484,620)
Balance at December 31, 2022	63,820	64	77,907,471	(71,960,227)	5,947,308
Fair value of vested stock options issued to employees and directors	-	-	152,599	-	152,599
Proceeds from sale of common stock in public offering, net of offering costs $684,839	459,643	459	5,043,702	-	5,044,161
Exercise of warrants	10,775	11	(11)	-	-
Extinguishment of warrant liability upon exercise of warrants	-	-	711,024	-	711,024
Net Loss	-	-	-	(8,948,731)	(8,948,731)
Balance at December 31, 2023	534,238	$534	$83,814,785	$(80,908,958)	$2,906,361

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.